

Daniel H Ahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2471845/publications.pdf>

Version: 2024-02-01

30
papers

526
citations

777949

13
h-index

759306

22
g-index

30
all docs

30
docs citations

30
times ranked

1084
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
2	Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6
3	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
4	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
5	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	3.4	6
6	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10
7	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	1.3	17
8	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	1.3	8
9	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
10	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
11	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	0.5	26
12	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	3.2	43
13	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	0.5	24
14	Metastatic Neuroendocrine Tumor with Cardiac Involvement Utilizing Multi-Modality Imaging. <i>Korean Circulation Journal</i> , 2019, 49, 557.	0.7	1
15	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. <i>Chinese Clinical Oncology</i> , 2019, 8, S19-S19.	0.4	1
16	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22
17	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	2.3	7
18	Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21.	2.3	27

#	ARTICLE	IF	CITATIONS
19	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
20	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018, 10, 193.	1.7	16
21	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	2.0	29
22	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 75-82.	1.4	46
23	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. <i>Biomedicines</i> , 2017, 5, 10.	1.4	10
24	Response to Drs Von Hoff and Renschler. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 445-446.	1.4	0
25	Therapeutic options for intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 91-100.	0.7	13
26	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
27	Oncolytic virotherapy in upper gastrointestinal tract cancers. <i>Oncolytic Virotherapy</i> , 2017, Volume 7, 13-24.	6.0	11
28	A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4018-4018.	0.8	9
29	Targeting the stroma in pancreatic cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 65-65.	0.4	7
30	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 260-265.	1.0	0